See what computational analyses actually reported, with provenance for every claim.Know what the science actually supports before you trust the answer.
Press Enter ↵ to search claims
Explore by Goal
"Biology gives you a brain. Life turns it into a mind."
- Jeffrey Eugenides
Quick Analysis Plan
Copied
AMYPdb “pattern counts vs CF thresholds” — rigorous interpretation plan
You’ll treat CF (pattern fitness) as a thresholded confidence metric and quantify how many AMYPdb patterns cross each CF cutoff, then map those counts to family-level enrichment and false-positive risk using sensitivity/specificity trends reported by AMYPdb. Evidence baseline: AMYPdb builds amyloid families and 3,621 sequence patterns (including 38 PROSITE patterns) and evaluates pattern fitness with Sen, Spe, and CF, while reporting a count of patterns with CF ≥ 0.9.
Goal: interpret how CF-thresholding changes which AMYPdb sequence patterns are “accepted”, and what that implies for family-level assignment confidence and downstream biological conclusions.
1) Define exactly what CF-thresholding means in AMYPdb (no assumptions)
Collect AMYPdb’s definitions for CF and how it is computed from Sen/Spe (AMYPdb states CF is used alongside Sen and Spe for pattern fitness).
Confirm the operational threshold you’ll use (e.g., CF ≥ 0.9), because AMYPdb explicitly reports a database-level count of patterns meeting CF ≥ 0.9.
2) Data model for “pattern counts vs CF thresholds”
You will build one tidy table where each row corresponds to a CF threshold and stores counts at multiple granularities:
CF threshold
# patterns passing
# amyloid families represented
family-level passing density (per family)
notes (gray-zone / sensitivity tradeoff)
Data will be filled by querying AMYPdb pattern fitness outputs (per-pattern CF, Sen, Spe) and mapping patterns to their amyloid family assignments. (AMYPdb provides the database scale; per-pattern CF values are required for real counts.)
3) Visualizations you should generate (once you have per-pattern CF values)
To interpret “CF-thresholds”, you want to see how acceptance set size changes and whether it concentrates in a subset of families.
A. Passing-set growth: #patterns vs CF cutoff
B. Family coverage: #families represented vs CF cutoff
C. Heatmap: families × CF bins (how concentrated the accepted patterns become)
4) Interpretation framework: what changes as CF threshold increases?
Set-size effect (coverage vs stringency): as CF threshold rises, the accepted pattern set shrinks. AMYPdb provides a concrete reference point: CF ≥ 0.9 yields 956 patterns out of 3,621 total.
Family representation effect: higher CF cutoffs may disproportionately keep patterns from certain amyloid families while dropping others—this can bias downstream “family assignment” toward families with easier-to-discriminate signatures.
Sensitivity/specificity tradeoff: because AMYPdb evaluates pattern fitness with Sen and Spe alongside CF, you should interpret CF thresholds in the context of the Sen/Spe performance profile (e.g., “high CF” might still have low sensitivity for certain family contexts).
5) Skeptical checks / likely blind spots (what could mislead your CF-count interpretation)
Database composition bias: AMYPdb is built from public resources (UniProtKB, MEDLINE, PROSITE), so differences in coverage across organisms/families can affect pattern discovery and CF statistics.
Pattern discovery dependence: pattern fitness depends on the particular amino-acid clusters and PRATT-based discovery setup used by AMYPdb; CF therefore is not a universal property of an underlying biology alone.
Cross-family comparability: counting “passing patterns” across families may conflate families with more candidate sequences and families with more distinct motifs. Use normalization (patterns-per-family opportunity) rather than raw counts when comparing families.
In vivo aggregation limitation: AMYPdb is a sequence-signature resource; it may not directly predict in vivo aggregation propensity without contextual biological data.
6) Practical coding workflow (what BGPT should run once it can access AMYPdb exports)
Ingest per-pattern fitness table (pattern_id, amyloid family, CF, Sen, Spe). Source: AMYPdb’s pattern outputs (requires pulling the dataset or scraping/exporting from AMYPdb).
Create CF threshold grid (e.g., CF ≥ 0.5, 0.6, 0.7, 0.8, 0.9, and any AMYPdb-relevant cut points). Ensure you include CF ≥ 0.9 since AMYPdb reports its global passing count (956 patterns).
Compute counts: passing patterns per CF threshold; passing families per threshold; and (key) normalized family representation metrics.
Overlay Sen/Spe with CF: within each CF bin, summarize Sen and Spe distributions to determine whether higher CF indeed corresponds to improved discriminative performance for the patterns retained.
Report uncertainty: because pattern fitness metrics depend on dataset construction, include a sensitivity analysis showing how counts change under slight threshold perturbations (e.g., ±0.01 around your CF cutoffs).
Run AI Scientist (to compute the real pattern counts & CF-threshold plots)
Your provided research data include AMYPdb aggregate totals (e.g., patterns and CF ≥ 0.9 count), but not the per-pattern CF values needed to compute the “pattern counts vs CF thresholds” curve. The agent will retrieve/parse AMYPdb per-pattern CF metrics (or use your uploaded exports if available), then generate the actual threshold curves and family-level enrichment plots without fabricating data.
You will load AMYPdb per-pattern fitness (CF, Sen, Spe), apply a grid of CF cutoffs, compute passing-pattern and family-coverage counts, and plot threshold curves plus Sen/Spe summaries to interpret selection effects.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
“CF ≥ 0.9 implies uniform high reliability across all amyloid families.” This is unlikely because pattern discovery and input database representation differ across families, and CF is computed within that pipeline context.
“Counts of passing patterns can be directly equated to biological prevalence of amyloid.” This likely fails because signature detectability is a property of motif presence and database coverage, not biological prevalence.
Quick Analysis Plan
Long Analysis Plan
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
